IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis

Nature Genetics

Volumn 49, Issue 5, 2017, Pages 795-800

  Eslam, Mohammed ^a   McLeod, Duncan ^b   Kelaeng, Kebitsaone Simon ^a   Mangia, Alessandra ^c   Berg, Thomas ^d   Thabet, Khaled ^a,e   Irving, William L ^f   Dore, Gregory J ^g   Sheridan, David ^h   Grønbæk, Henning ⁱ   Abate, Maria Lorena ^j   Hartmann, Rune ^k   Bugianesi, Elisabetta ^j   Spengler, Ulrich ^l   Rojas, Angela ^m   Booth, David R ^a   Weltman, Martin ⁿ   Mollison, Lindsay ^o   Cheng, Wendy ^p   Riordan, Stephen ^q   Mahajan, Hema ^b   Fischer, Janett ^d   Nattermann, Jacob ^l   Douglas, Mark W ^a,r   Liddle, Christopher ^a   Powell, Elizabeth ^s   Romero Gomez, Manuel ^m   George, Jacob ^a   Metwally, Mayada ^a   White, Rose ^a   Gallego Duran, Rocio ^m   Leung, Reynold ^a   Mahajan, Neha ^b   Bassendine, Margaret ^h   Rahme, Antony ^a   Rosso, Chiara ^j   Mezzabotta, Lavinia ^j   Malik, Barbara ^d   Matthews, Gail ^g   Asimakopoulos, Anastasia ^a   Applegate, Tanya ^g   Grebely, Jason ^g   Fragomeli, Vincenzo ^l   Jonsson, Julie R ^g   Santoro, Rosanna ^c   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e Minia University   (Egypt)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h UNIVERSITY OF PLYMOUTH   (United Kingdom)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^j UNIVERSITY OF TURIN   (Italy)

^k AARHUS UNIVERSITY   (Denmark)

^l UNIVERSITY OF BONN   (Germany)

^m HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁿ NEPEAN HOSPITAL   (Australia)

^o FREMANTLE HOSPITAL   (Australia)

^p ROYAL PERTH HOSPITAL   (Australia)

^q UNIVERSITY OF NEW SOUTH WALES   (Australia)

^r University of Sydney   (Australia)

^s UNIVERSITY OF QUEENSLAND   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON LAMBDA 3; INTERFERON LAMBDA 4; PROTEIN VARIANT; UNCLASSIFIED DRUG; IFNL4 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CELL INFILTRATION; DISEASE COURSE; GENOTYPE; HAPLOTYPE; HEPATIC STELLATE CELL; HEPATITIS; HUMAN; IMMUNOCOMPETENT CELL; LIVER FIBROSIS; MACROPHAGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; FIBROSIS; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETICS; HEPACIVIRUS; HEPATITIS C; INFLAMMATION; LIVER; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL MODEL; VIROLOGY;

FIBROSIS; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HEPACIVIRUS; HEPATITIS C; HUMANS; INFLAMMATION; INTERLEUKINS; LINKAGE DISEQUILIBRIUM; LIVER; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 85017214859     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3836     Document Type: Article

References (44)

1. Bochud, P.Y. et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 55, 384-394 (2012).
2. Eslam, M. et al. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat. Commun. 6, 6422 (2015).
3. Eslam, M. et al. FibroGENE: a gene-based model for staging liver fibrosis. J. Hepatol. 64, 390-398 (2016).
4. Thompson, A.J. et al. Genome wide-association study identifies Il28b polymorphism to be associated with baseline alt and hepatic necro-inflammatory activity in chronic hepatitis C patients enrolled in the Ideal Study. Hepatology 52, 1220a-1221a (2010).
5. Prokunina-Olsson, L. et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45, 164-171 (2013).
6. McFarland, A.P. et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat. Immunol. 15, 72-79 (2014).
7. Iredale, J.P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest. 117, 539-548 (2007).
8. Wack, A., Terczyńska-Dyla, E. & Hartmann, R. Guarding the frontiers: the biology of type III interferons. Nat. Immunol. 16, 802-809 (2015).
9. Baldridge, M.T. et al. Commensal microbes and interferon-λ determine persistence of enteric murine norovirus infection. Science 347, 266-269 (2015).
10. Mordstein, M. et al. λ interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J. Virol. 84, 5670-5677 (2010).
11. Thomas, E. et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 142, 978-988 (2012).
12. Park, H. et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 56, 2060-2070 (2012).
13. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
14. Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet. 41, 1100-1104 (2009).
15. Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109 (2009).
16. Rauch, A. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138, 1338-1345 (2010).
17. + regulatory T cells. PLoS One 7, e44915 (2012).
18. Aoki, Y. et al. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. J. Gastroenterol. 50, 894-902 (2015).
19. Aboulnasr, F. et al. IFN-λ inhibits miR-122 transcription through a Stat3-HNF4α inflammatory feedback loop in an IFN-α resistant HCV cell culture system. PLoS One 10, e0141655 (2015).
20. Chandra, P.K. et al. Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. PLoS One 9, e108616 (2014).
21. Friborg, J. et al. Impairment of type I but not type III IFN signaling by hepatitis C virus infection influences antiviral responses in primary human hepatocytes. PLoS One 10, e0121734 (2015).
22. Honda, M. et al. Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. Hepatology 59, 828-838 (2014).
23. Langhans, B. et al. Interferon-λ serum levels in hepatitis C. J. Hepatol. 54, 859-865 (2011).
24. Dill, M.T. et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140, 1021-1031 (2011).
25. + dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus. Hepatology 57, 1705-1715 (2013).
26. Murata, K. et al. Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients. J. Gastroenterol. 49, 126-137 (2014).
27. Watanabe, T. et al. Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. Gut 62, 1340-1346 (2013).
28. Urban, T.J. et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52, 1888-1896 (2010).
29. Rallón, N.I. et al. Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. J. Antimicrob. Chemother. 67, 1246-1249 (2012).
30. Shi, X. et al. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One 7, e37054 (2012).
31. Lu, Y.F. et al. IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci. Rep. 5, 16037 (2015).
32. Onabajo, O.O. et al. Expression of interferon λ4 is associated with reduced proliferation and increased cell death in human hepatic cells. J. Interferon Cytokine Res. 35, 888-900 (2015).
33. Lu, Y.F., Goldstein, D.B., Urban, T.J. & Bradrick, S.S. Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden. Virology 476, 334-340 (2015).
34. Hamming, O.J. et al. Interferon λ4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 32, 3055-3065 (2013).
35. Terczyńska-Dyla, E. et al. Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat. Commun. 5, 5699 (2014).
36. O'Brien, T.R. et al. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J. Hepatol. 63, 1103-1110 (2015).
37. Poynard, T. et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J. Hepatol. 34, 730-739 (2001).
38. Lauber, C. et al. Transcriptome analysis reveals a classical interferon signature induced by IFNλ4 in human primary cells. Genes Immun. 16, 414-421 (2015).
39. Pellicoro, A., Ramachandran, P., Iredale, J.P. & Fallowfield, J.A. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 14, 181-194 (2014).
40. Kazankov, K. et al. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology 60, 521-530 (2014).
41. Bedossa, P. & Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24, 289-293 (1996).
42. Eslam, M. et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J. Hepatol. 61, 235-241 (2014).
43. Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
44. Skol, A.D., Scott, L.J., Abecasis, G.R. & Boehnke, M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat. Genet. 38, 209-213 (2006).